Multicenter evaluation of the analytical and clinical performance of the Elecsys® S100 immunoassay in patients with malignant melanoma

Clinical Chemistry and Laboratory Medicine

Volumn 43, Issue 5, 2005, Pages 557-563

  Alber, Bettina ^a,c   Hein, Rüdiger ^a   Grabe, Claus ^b   Caroli, Ulrich ^b   Luppa, Peter B ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c KLINIKUM NÜRNBERG   (Germany)

Author keywords

Malignant melanoma; S100; Tumor marker

Indexed keywords

PROTEIN S 100; TUMOR MARKER;

ARTICLE; BLOOD SAMPLING; CALCULATION; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONSTANTS AND COEFFICIENTS; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; FOLLOW UP; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MELANOMA; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; REFERENCE VALUE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; ADULT; AGED; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; ELECTROCHEMISTRY; EVALUATION; FEMALE; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; SKIN TUMOR; STATISTICS;

ADULT; AGED; CHEMILUMINESCENT MEASUREMENTS; ELECTROCHEMISTRY; FEMALE; HUMANS; IMMUNOASSAY; MALE; MELANOMA; MIDDLE AGED; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 23044481577     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2005.097     Document Type: Article

References (21)

1. Glass AG, Hoover RN. The emerging epidemic of melanoma and squamous cell carcinoma. Br J Cancer 1998;78:40-5.
2. Rivers JK. Melanoma. Lancet 1996;347:803-6.
3. Gaynor R, Irie R, Morton D, Herschman HR. S100 protein is present in cultured human malignant melanomas. Nature 1980;286:400-1.
4. Cochran AJ, Wen DR, Herschman HR. Detection of S-100 protein as an aid to the identification of melanocytic tumours. Int J Cancer 1982;30:295-7.
5. Schäfer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci 1996;21:134-40.
6. Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res Bull 1995;4:417-29.
7. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Technique 2003;60:540-51.
8. Guo HB, Stoffel-Wagner B, Bierwirth T, Metzger J, Klingmüller D. Clinical significance of Serum S100 in metastatic malignant melanoma. Eur J Cancer 1995;31A:924-8.
9. Kaskel P, Berking C, Sander S, Volkenandt M, Peter RU, Krähn G. S-100 protein in peripheral blood: a marker for melanoma metastases. J Am Acad Dermatol 1999; 41:962-9.
10. Mohammed MQ, Abraha HD Sherwood RA, MacRae K, Retsas S. Serum S100β protein as a marker of disease activity in patients with malignant melanoma. Med Oncol 2001;18:109-20.
11. Krähn G, Kaskel P, Sander S, Pereira Y, Waizenhöfer J, Wortmann S, et al. S100β is a more reliable tumor marker in peripheral blood with newly occurred melanoma metastases compared with MIA, albumin and lactate dehydrogenase. Cancer Res 2001;21:1311-6.
12. von Shoultz E, Hansson LO, Djureen E, Hansson J, Nilsson B, Stigbrand T, et al. Prognostic value of serum analysis S-100 protein in malignant melanoma. Melanoma Res 1996;6:133-7.
13. Abraha HD, Fuller LC, Vivier AW, Higgins EM, Sherwood RA. Serum-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br J Dermatol 1997; 46:381-5.
14. Bablok W, Passing H, Bender R, Schneider B. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry. J Clin Chem Clin Biochem 1988;26:783-90.
15. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
16. Schlagenhauff B, Schittek B, Ellwanger U, Stroebel W, Blum A, Rassner G, et al. Significance of serum protein S100 levels in screening for melanoma metastasis: does protein S100 enable early detection of melanoma recurrence? Melanoma Res 2000;10:451-9.
17. Jury CS, McAllister EJ, MacKie RM. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol 2000;143:269-74.
18. Schultz ES, Diepgen TL, von den Driesch P. Clinical and prognostic relevance of serum S-100β protein in malignant melanoma. Br J Dermatol 1998;138:426-30.
19. Persson L, Hardemark HG, Gustafsson J, Rundstrom G, Mendel-Hartvig I, Escher T, et al. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke 1987;18:911-8.
20. Otto M, Stein H, Szudra A, Zerr I, Bodemer M, Gefeller O, et al. S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurol 1997;244:566-70.
21. Molina R, Navarro J, Filella X, Castel T, Ballesta AM. S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function. Tumor Biol 2002;23:39-44.